In the News

Article

Recce Pharmaceuticals doses all patients in phase II skin infection trial

Published 29 Jan 2025

Article

Recce Pharmaceuticals doses all patients in Phase 2 clinical trial of RECCE® 327 topical gel for skin infections

Published 21 Jan 2025

Article

Recce gets Indonesian nod for phase III trial of diabetic foot infection treatment

Published 09 Dec 2024

Article

Complete patent protection for 2 Recce anti-infective treatments

Published 26 Nov 2024

Article

Recce green lit to begin dosing in registrational Phase 3 trial for diabetic foot infections

Published 11 Nov 2024

Article

From No More Tears to no more superbug fears

Published 21 Oct 2024

Article

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Published 16 Oct 2024

Article

Local Pharma Fights Superbugs

Published 14 Oct 2024

Article

Recce’s Phase 2 trial for skin infections hits midway recruitment milestone

Published 09 Oct 2024

Article

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Published 02 Oct 2024

Article

Recce Pharmaceuticals Advances Antibiotic Development to Combat Antimicrobial Resistance

Published 09 Sep 2024

Article

Recce’s reconnaissance against superbug – infiltrate, eliminate, escape undetected

Published 09 Sep 2024

Article

Recce Pharmaceuticals Delivers the Opening Address at World Antimicrobial Resistance Congress 2024

Published 06 Sep 2024

Article

Recce Pharmaceuticals – Executive Interview

Published 07 Aug 2024

Article

Recce Pharmaceuticals more than doubles SPP target with A$4.4 million taking raise proceeds to A$12.4 million

Published 05 Aug 2024

Article

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Published 16 Jul 2024

Article

Recce Pharmaceuticals granted US$2 million from US Department of Defense for RECCE® 327 Gel

Published 15 Jul 2024

Article

Recce Pharmaceuticals reports positive data from Phase 1/2 UTI/urosepsis rapid infusion clinical trial of RECCE® 327

Published 28 Jun 2024

Article

Recce Starts Phase 2 R327 Gel trial for bacterial skin infections

Published 25 Jun 2024

Article

Recce Pharmaceuticals lands WHO Antibacterial Products in Clinical Development listing for RECCE® 327

Published 18 Jun 2024

Article

Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound

Published 12 Jun 2024

Article

Recce wraps up IV UTI trial with fastest infusion times yet; key safety review inbound

Published 11 Jun 2024

Article

Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market

Published 27 May 2024

Article

Recce Pharma heading closer to full efficacy data for flagship R327

Published 15 May 2024

Article

Recce Pharmaceuticals makes breakthrough in lung infection treatment with nebulised RECCE® 327

Published 09 May 2024

Article

Recce Pharma picks up Chinese patent for anti-infective drugs

Published 07 May 2024

Article

Recce weighs in on Q1 2024 as cash increases 100%

Published 22 Apr 2024

Article

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Published 16 Apr 2024

Article

Recce Pharmaceuticals selected to participate in UK Government Innovation Agency’s AMR Mission 2024

Published 11 Apr 2024

Article

Recce gearing up for Indonesian trials; US DOD looking at R327 burn gel

Published 09 Apr 2024

Article

Recce gearing up for Indonesian trials; US DOD looking at R327 burn gel

Published 08 Apr 2024

Article

Recce Pharmaceuticals inks new patent for flagship drug in Israel

Published 03 Apr 2024

Article

Recce reaches testing milestone for UTI, Uroseptis antibiotic

Published 22 Mar 2024